Autoimmune Hepatitis

Authored by , Reviewed by Dr Laurence Knott | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Autoimmune Hepatitis article more useful, or one of our other health articles.


Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Autoimmune hepatitis (AIH) is a rare and chronic liver disease that is characterised by increased serum transaminases and immunoglobulin G, inflammatory liver histology and presence of circulating autoantibodies[1].

Immune serum markers are often present and the disease is often associated with other autoimmune diseases.

  • AIH is associated with the complement allele C4AQO and with the HLA haplotypes B8, B14, DR3, DR4, and Dw3.
  • The autoantibodies present include antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), anti-liver-kidney microsomal-1 (anti-LKM-1) antibody, antibodies against soluble liver antigen (anti-SLA), antimitochondrial antibody (AMA) and antiphospholipid antibodies.

AIH is an heterogeneous disorder and it can be divided into two types, depending on which autoantibodies are present:

  • Type 1: associated with the presence of ASMA or ANA. Accounts for about 75% of patients[2].
  • Type 2: associated with the presence of either anti-LKM-1 or anti-liver cytosolic-1 (anti-LC-1) antibodies[3].

AIH may have cholestatic features that are outside the classical phenotype and resemble findings in other autoimmune liver diseases. These cholestatic phenotypes are called 'overlap syndromes'[4].

Juvenile AIH is a progressive inflammatory liver disease, affecting mainly young girls from infancy to late adolescence, and characterised by active liver damage, with high serum activity of aminotransferases, raised immunoglobulin G levels, high titres of serum non-organ-specific and organ-specific autoantibodies, and by interface hepatitis on liver biopsy[5].

  • The prevalence of AIH in Europe is estimated as being in the range of 10-17 cases per 100,000 persons[6].
  • AIH occurs worldwide with a low and probably underestimated prevalence. Although it typically affects young and middle-aged women, it can occur in both sexes and can affect all age groups[7].

Presentation can be acute, severe (fulminant), asymptomatic or chronic[8].

Subclinical disease often precedes the onset of symptoms and many patients have histological evidence of cirrhosis at the onset of symptoms. Common symptoms include:

  • Fatigue, myalgia, mild pruritus.
  • Nausea (often a prominent symptom).
  • Upper abdominal discomfort.
  • Anorexia, diarrhoea.
  • Arthralgias.
  • Skin rashes (including acne), hirsutism.
  • Oedema.
  • Amenorrhoea.
  • Chest pain (pleuritis).
  • Weight loss and intense pruritus (unusual).

Signs

Common findings on physical examination are as follows:

  • Hepatomegaly.
  • Jaundice (around 50% of patients).
  • Splenomegaly.
  • Spider angiomata.
  • Ascites.
  • Encephalopathy.

No pathognomonic features exist for AIH and therefore the diagnosis rests on a combination of compatible biochemical, immunological and histological features together with exclusion of other liver diseases[6].

Diagnosis of autoimmune liver disease requires the exclusion of common viral, drug-induced and metabolic liver disease. The classical features of AIH are elevated aminotransferases, raised IgG-positive auto-antibodies, and interface hepatitis with portal plasma cell infiltrate on biopsy. However, the histology findings are not specific for the diagnosis of AIH[9].

  • Autoantibodies (see above).
  • Serum protein electrophoresis and quantitative immunoglobulins:
    • An IgG-predominant polyclonal hypergammaglobulinaemia is a common finding in patients with untreated AIH.
    • Increased gammaglobulin and IgG levels are found in around 85% of patients.
    • Immunoglobulin levels typically return to normal during treatment.
  • Aminotransferases:
    • Serum aminotransferases: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are usually elevated at initial presentation.
    • Aminotransferase values correlate poorly with the degree of hepatic necrosis but very high levels may indicate acute hepatitis or a severe flare of pre-existing disease.
    • Continued elevation of the aminotransferases during therapy is a reliable marker for ongoing liver inflammation but active liver inflammation is present in more than 50% of patients with normal LFTs. Biochemical remission may precede true histological remission by 3-6 months.
    • Serum aminotransferases may normalise either on treatment or spontaneously, even with continuing severe hepatic inflammation on biopsy.
  • Serum alkaline phosphatase is normal or only mildly raised. A more than two-fold elevation suggests an alternative or additional diagnosis.
  • Hypoalbuminaemia and prolongation of prothrombin time are markers of severe hepatic synthetic dysfunction.
  • FBC and blood film: findings include mild leukopenia, normochromic anaemia, Coombs-positive haemolytic anaemia, thrombocytopenia, eosinophilia.
  • Imaging studies are not usually helpful in reaching a definitive diagnosis of AIH but may suggest the presence of active inflammation or necrosis. The appearance of an irregular nodular liver may confirm the presence of cirrhosis. Imaging studies may also be used to rule out the presence of hepatocellular carcinoma.
  • Liver biopsy[10]:
    • Liver biopsy is the most important diagnostic procedure in patients with AIH.
    • Liver biopsy should be performed as early as possible in all patients with acute hepatitis who are thought to have AIH. Confirmation of the diagnosis enables initiation of treatment at an early stage in the disease process.
    • Liver biopsy also provides information on prognosis. Up to a third of patients have cirrhosis at presentation[2]. Patients with cirrhosis and those with bridging necrosis at diagnosis have a poorer prognosis than those without.

Concurrent autoimmune disorders occur in approximately 40% of patients, particularly autoimmune thyroid disorder[11].

Autoimmune hepatitis requires lifelong treatment in most patients in order to prevent development of cirrhosis and end-stage liver disease.

The cornerstone of treatment is steroid induction therapy followed by maintenance therapy with azathioprine, which is effective in most cases.

For patients who do not respond to standard treatment, second-line treatment with other immunosuppressants can be effective.

Treatment should be aimed at biochemical remission of the disease, which is defined as normalisation of transaminases and immunoglobulin G.

Patients should be monitored intensively during the first months of treatment in order to monitor side-effects, assess symptoms and individualise treatment.

Liver transplantation[12]

Liver transplantation is indicated for terminal phases of autoimmune hepatitis. Therapeutic advances have reduced the need for transplantation for AIH. Recurrence of AIH may occur after liver transplantation.

Monitoring

  • Patients should be tested for hepatitis A and B immunity and vaccinated if needed.
  • Regular blood testing including LFTs, glucose and FBC should be performed.
  • All patients should receive calcium and vitamin D supplements.
  • Dual-energy X-ray absorptiometry (DXA) scans should be performed prior to starting steroids and repeated at 1- to 2-yearly intervals.
  • Screening for glaucoma and cataracts should be considered after 12 months of prednisolone treatment.
  • Hyperviscosity syndrome secondary to high IgG levels may occur.
  • Hepatocellular carcinoma may occur. It is more common in patients with cirrhosis. There is a 10-20% risk of hepatocellular carcinoma in patients with cirrhosis[13].
  • Six-monthly surveillance is recommended to be undertaken in otherwise healthy patients with cirrhosis, using ultrasound and serum alpha-fetoprotein[14].
  • Without treatment, nearly 50% of patients with severe AIH die in approximately five years[15].
  • Outlook for treated patients with AIH is generally very good[16].
  • However, presentation and outcome are variable[17].
  • Some patients receive a maintenance dose of azathioprine or azathioprine and prednisolone which has been shown to reduce the risk of relapse[18].
  • Recurrent disease after liver transplantation has been reported in 10-50% of patients with AIH[19].
  • Cirrhosis develops in up to 50% of patients with AIH.

Further reading and references

  1. Pape S, Schramm C, Gevers TJ; Clinical management of autoimmune hepatitis. United European Gastroenterol J. 2019 Nov7(9):1156-1163. doi: 10.1177/2050640619872408. Epub 2019 Aug 25.

  2. Al-Chalabi T, Underhill JA, Portmann BC, et al; Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008 Jan48(1):140-7. Epub 2007 Oct 22.

  3. Granito A, Muratori P, Ferri S, et al; Diagnosis and therapy of autoimmune hepatitis. Mini Rev Med Chem. 2009 Jun9(7):847-60.

  4. Czaja AJ; Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013 Jul27(7):417-23.

  5. Maggiore G, Nastasio S, Sciveres M; Juvenile autoimmune hepatitis: Spectrum of the disease. World J Hepatol. 2014 Jul 276(7):464-76. doi: 10.4254/wjh.v6.i7.464.

  6. Guidelines for the Management of Autoimmune Hepatitis; British Society of Gastroenterology (May 2011)

  7. Francque S, Vonghia L, Ramon A, et al; Epidemiology and treatment of autoimmune hepatitis. Hepat Med. 2012 Mar 164:1-10. doi: 10.2147/HMER.S16321.

  8. Czaja AJ; Diagnosis and Management of Autoimmune Hepatitis. Clin Liver Dis. 2015 Feb19(1):57-79. doi: 10.1016/j.cld.2014.09.004. Epub 2014 Nov 21.

  9. Dyson JK, Webb G, Hirschfield GM, et al; Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015 Jan62(1):208-218. doi: 10.1016/j.jhep.2014.09.010. Epub 2014 Sep 16.

  10. Sharma S, Khalili K, Nguyen GC; Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol. 2014 Dec 720(45):16820-16830.

  11. Carbone M, Neuberger JM; Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014 Jan60(1):210-23. doi: 10.1016/j.jhep.2013.09.020. Epub 2013 Sep 29.

  12. Ilyas JA, O'Mahony CA, Vierling JM; Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol. 2011 Dec25(6):765-82. doi: 10.1016/j.bpg.2011.09.008.

  13. Montano-Loza AJ, Carpenter HA, Czaja AJ; Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008 Aug103(8):1944-51. Epub 2008 Jun 28.

  14. Manns MP, Czaja AJ, Gorham JD, et al; Diagnosis and management of autoimmune hepatitis. Hepatology. 2010 Jun51(6):2193-213.

  15. Decock S, McGee P, Hirschfield GM; Autoimmune liver disease for the non-specialist. BMJ. 2009 Sep 8339:b3305. doi: 10.1136/bmj.b3305.

  16. Strassburg CP, Manns MP; Treatment of autoimmune hepatitis. Semin Liver Dis. 2009 Aug29(3):273-85. Epub 2009 Aug 12.

  17. Czaja AJ; Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol. 2013 Sep27(9):531-9.

  18. Lamers MM, van Oijen MG, Pronk M, et al; Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010 Jul53(1):191-8. Epub 2010 Mar 30.

  19. Stirnimann G, Ebadi M, Czaja AJ, et al; Recurrent and De Novo Autoimmune Hepatitis. Liver Transpl. 2019 Jan25(1):152-166. doi: 10.1002/lt.25375.

newnav-downnewnav-up